Antibiotics

Erlinda Ulloa, MD, discusses a severe case including how they secured the phage treatment, and her experience with the investigational therapy.

Ken Duncan, PhD, discussed the launch of a $50 million initiative focused on developing new drugs for critical pathogens contributing to antimicrobial resistance.

Todd Riccobene, PhD, senior scientific director, Anti-Infectives and Infectious Diseases, US Medical Affairs + Health Impact at AbbVie provides more information on the newly approved antibiotic combination for these infections.

Jeffrey Freiberg, MD, PhD review of the SABATO trial on oral antibiotics for S aureus bacteremia and a comparison of mupirocin and iodine treatments for MRSA decolonization.

Jeffery Freiberg, MD, PhD review on key trials and challenges from 2024 in the fight against antibiotic resistance in complicated and uncomplictaed UTIs, including cefepime-taniborbactam and gepotidacin.

Here are some strategies to consider for optimal utilization.

The company’s investigational gel, RECCE 327, met primary and secondary endpoints, and it plans to progress to a phase 3 trial.

An inoculum effect in methicillin-susceptible S aureus infective endocarditis is suspected factor in higher all-cause 30-day mortality with cephazolin treatment than with oxacillin.

A decreasing number of researchers and open positions for infectious disease clinicians and limited residency matches are underlying issues that should be addressed to meet the needs around antimicrobial development and clinical care. Amesh Adalja, MD, FIDSA, discusses some of the challenges behind it.

Hannah Pye, PhD and Evelien Adriaenssens, PhD explore the potential of phages in combating antimicrobial resistance and advancing health across human, animal, and environmental domains.

Heather Platt, MD, discusses Merck’s latest achievement with Capvaxive and its potential to significantly reduce invasive pneumococcal disease and pneumonia in high-risk adult populations across Europe.

This combination antibiotic is indicated for adults with limited or no treatment options, including gram-negative infections. It will be available in the third quarter of this year.

Fecal microbiota transplantation emerges as the top treatment, while probiotics show limited effectiveness in preventing CDI recurrence.

Robert Allen, MD, on variant monitoring, antibody development, and the company's long-term approach to patient care.

Robert Allen, PhD, discusses how Pemgarda’s stability in targeting the spike protein's receptor-binding domain offers crucial protection, including immunocompromised individuals.

Gregory Fox, PhD discusses the V Quinn trial's results, exploring levofloxacin’s role in reducing TB incidence and the study's approach to combining data with the TB Champ trial.

Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.

Vaccines and treatments are up for approval in early to mid-2025, including a chikungunya vaccine, a meningococcal vaccine, a monoclonal antibody for RSV, and more.

Oral omadacyline or linezolid was equally efficacious to intravenous dosing for acute bacterial skin infections, and associated with less cost and risks.

Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.

Abdulwhab Shremo Msdi, PharmD, offers insights on its complexities, why institutions have been slower to include this dosing technique, and why clinicians need to consider this approach.

In a retrospective cohort study, a health system found this form of prophylaxis led to substantial reductions in 2 of 3 sexually transmitted infections (STIs) in a mostly male population.

New recommendations emphasize shorter, all-oral regimens for both drug-susceptible and drug-resistant TB.

Investigators propose limiting initial use of antibiotics for group A streptococcal pharyngitis in children after finding placebo noninferior in reducing symptoms.

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.